New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma

In this online program experts discuss how to best use new therapeutic agents for patients with relapsed/refractory multiple myeloma. Watch the on-demand Webcast and download the slides from a dynamic online live CCO symposium plus access expert commentaries and a podcast on the new data to learn more about how to select optimal regimens for your patients with advanced myeloma.

This educational program is intended for clinicians practicing medicine outside of the United States.

Share

Program Content

Activities

FAQ: Myeloma Therapeutics
FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: September 03, 2020

Expires: September 02, 2021

Activities

New Therapy for RR MM
New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma
Congratulations: You achieved a completion on 04/09/2022

Activities

Tx of Early R/R MM
Available Therapeutic Strategies for Patients With Early Relapsed, Refractory Multiple Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 15, 2020

Expires: July 14, 2021

Tx of Late R/R MM
Promising New/Novel BCMA-Targeted Treatment Options for Patients With Late Relapsed, Refractory Multiple Myeloma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 16, 2020

Expires: July 15, 2021

Novel Tx of R/R MM
Therapeutic Developments for Relapsed/Refractory Multiple Myeloma: Other Novel Agents With New Targets
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 20, 2020

Expires: July 19, 2021

Activities

Belantamab Mafodotin for R/R MM
My Take on the Recent Approval of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 25, 2020

Expires: August 24, 2021

MM Biochemical Relapse
Should We Treat Biochemical Relapse in Multiple Myeloma?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 22, 2020

Expires: September 21, 2021

Faculty

cover img faculity

Paula Rodriguez-Otero, MD, PhD

Associate Professor
Consultant in Hematology

Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain

cover img faculity

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

cover img faculity

Jesus San-Miguel, MD, PhD

Director of Clinical and Translational Medicine
Clinica Universidad de Navarra
Universidad de Navarra
Pamplona, Spain

cover img faculity

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline